MedTrace Logo

Two Versus Four Weeks of Antibiotic Treatment in Native Joint Arthritis

NCT03615781 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 85

Last updated 2018-08-06

No results posted yet for this study

Summary

The optimal duration of systemic antibiotic administration for native joint septic arthritis is unknown. The investigators perform a randomized study allowing up to 3 surgical lavages and allocating patients into a two-week's and a four week's randomization arm

Conditions

  • Arthritis, Septic

Interventions

PROCEDURE

Two week's arm - surgery

The investigators perform a surgical drainage of the infection along with the complete removal of the infected orthopedic implant.

PROCEDURE

Four week's arm - surgery

The investigators perform a surgical drainage of the infection along with the complete removal of the infected orthopedic implant.

DRUG

Two week's arm - drugs

After the surgical implant removal, the investigators prescribe a total of 2 weeks of systemic targeted antibiotic therapy against the causative pathogen(s), of which one week is recommended to be intravenously.

DRUG

Four week's arm - drugs

After the surgical implant removal, the investigators prescribe a total of 4 weeks of systemic targeted antibiotic therapy against the causative pathogen(s), of which one week is recommended to be intravenously.

Sponsors & Collaborators

  • University Hospital, Geneva

    lead OTHER

Principal Investigators

  • Ilker Uçkay, MD · University Hospital, Geneva

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
120 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-06-01
Primary Completion
2018-04-01
Completion
2018-05-18

Countries

  • Switzerland

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03615781 on ClinicalTrials.gov